Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Deutsches Herzzentrum Muenchen |
---|---|
Information provided by: | Deutsches Herzzentrum Muenchen |
ClinicalTrials.gov Identifier: | NCT00402636 |
The purpose of this study is to evaluate whether adding estradiol to rapamycin better prevents coronary artery reblockage after drug-eluting stent implantation.
Condition | Intervention | Phase |
---|---|---|
Coronary Heart Disease |
Device: rapamycin plus 17beta estradiolvalerat-eluting stent Device: rapamycin-eluting stent |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Prospective, Randomized Trial of Rapamycin Plus Estradiol-Eluting Stents Versus Rapamycin-Eluting Stents For The Reduction of Coronary Restenosis (ISAR-PEACE) |
Enrollment: | 502 |
Study Start Date: | March 2005 |
Study Completion Date: | October 2006 |
Arms | Assigned Interventions |
---|---|
1: Experimental
rapamycin plus 17beta estradiolvalerat-eluting stent
|
Device: rapamycin plus 17beta estradiolvalerat-eluting stent
rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
|
2: Experimental
rapamycin-eluting stent
|
Device: rapamycin-eluting stent
rapamycin-eluting stent was implanted due to randomisation
|
Coronary artery reblockage remains still a drawback of percutaneous coronary interventions even in the era of drug-eluting stents (DES). DESs working principle consists of the delivery of controlled amounts of antiproliferative agents at the local level, which results in the suppression of neontimal proliferation, the main cause of lumen re-narrowing after stent implantation. At present, several DES platforms have been developed and evaluated for clinical use. They differ between them with regard to the stent type, anti-proliferative drug, presence or absence of polymers employed for drug storage and modification of drug-release kinetics as well as type of polymer used for this purpose. Although their mid-term efficacy has been well-established, there is an ongoing debate on the potential of an increased incidence of late stent thrombosis, particularly after discontinuation of thienopyridine therapy, as well as of delayed onset of restenosis or catch-up phenomenon with DESs. Based on animal and human pathological data, investigators have linked the above-mentioned concerns to the presence of permanent polymers in DESs, which have a proinflammatory and prothrombogenic potential, and sometimes may induce a hypersensitivity reaction. On the other hand, lack of or delayed reendothelialization is considered an important factor for development of coronary reblockage. Estradiol has been shown to promote rapid reendothelialization of the stent and to reduce the restenosis after PCI. This trial will compare the anti-restenotic efficacy of the polymer-free rapamycin plus 17β estradiolvalerat -eluting stent with that of the polymer-free rapamycin-eluting stent in patients with coronary artery disease. The ISAR stent is a rough surface stainless steel stent which allows coating without the need of polymer (PF ISAR stent) in the cath lab.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Deutsches Herzzentrum Muenchen | |
Munich, Germany, 80636 | |
1. Medizinische Klinik, Klinikum rechts der Isar | |
Muenchen, Germany, 81675 |
Study Chair: | Albert Schoemig, MD | Deutsches Herzzentrum Muenchen |
Principal Investigator: | Adnan Kastrati, MD | Deutsches Herzzentrum Muenchen |
Study ID Numbers: | GE IDE No. S02505 |
Study First Received: | November 21, 2006 |
Last Updated: | November 27, 2007 |
ClinicalTrials.gov Identifier: | NCT00402636 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Arterial Occlusive Diseases Sirolimus Heart Diseases Clotrimazole Miconazole Myocardial Ischemia Estradiol valerate Tioconazole Vascular Diseases |
Ischemia Arteriosclerosis Estradiol 17 beta-cypionate Coronary Restenosis Estradiol Coronary Disease Estradiol 3-benzoate Polyestradiol phosphate Coronary Artery Disease |
Anti-Bacterial Agents Anti-Infective Agents Immunologic Factors Antineoplastic Agents Antifungal Agents Therapeutic Uses |
Physiological Effects of Drugs Cardiovascular Diseases Antibiotics, Antineoplastic Immunosuppressive Agents Pharmacologic Actions |